Severity of prognosis factors in breast cancer cases was found to be associated with an increase in plasma vitamin E and a decrease in plasma malondialdehyde (peroxidability index). The first aim of this study was to determine whether this association is also present in other cancers. Measurements were taken before therapy on 129 patients with various carcinomas. Cholesterol was also investigated, as vitamin E is closely related to this analyte. Patients were classified by tumor size (T =£ 5 cm and T > 5 cm) and by invasion status, assessed by the presence of nodes and/or metastasis. The vitamin E/total cholesterol concentration ratio was higher and the cholesterol and malondialdehyde concentrations were significantly lower in the plasma of patients with large tumors or in whom nodes and/or metastasis were present, whatever the site. The multivariate analysis performed to measure the association of these analyte concentrations with tumor progression showed that the presence of nodes and/or metastases was inversely associated with a low vitamin E/total cholesterol ratio (OR, 0.5; CI, 0.3-1.1) and, directly associated with low plasma concentrations of cholesterol and malondialdehyde (OR, 3.0; CI, 1.3-6.8 and OR, 2.8; CI, 1.2-6.7 respectively). The same types of associations were identified with large tumors, but were less strong. Together these findings supported an alteration of lipid parameters related to the oxidantantioxidant status in cancer patients. This alteration appears to be associated with tumor growth and progression in patients with various cancer sites.
Introduction
The plasma concentration of various antioxidants, either vitamins (1-3) or enzymes (4), has been found to be higher in the plasma of cancer patients than in that of controls. We have previously shown, as a corollary, that malondialdehyde (MDA*), a lipid peroxidation marker, was lower in breast cancer patients than in controls (5), and Zaridze et al. (6) have shown that a decrease in breast cancer risk is associated with an increased level of polyunsaturated fatty acids in erythrocyte membranes from breast cancer patients. These findings were examined in the context of an hypothesis developed by Slater et al. (7) , who suggested that increased antioxidant capacities and decreased peroxidable substrates gave transformed cells a selective growth advantage. More recently it has been shown •Abbreviations: MDA, malondialdehyde; pTC, plasma total cholesterol; vitE/ pTC, vitamin E/total cholesterol ratio; OR, odds ratio; CI, 95% confidence interval.
© Oxford University Press that rapid proliferating normal cells possess the same characteristics (8) .
Furthermore, factors of tumor aggressiveness were found to be associated with a comparable alteration in oxidantantioxidant status: (i) chemotherapy-resistant tumor cells showed higher concentrations of glutathione enzymes (9) ; (ii) high vitamin E plasma concentrations and low MDA plasma concentrations were more closely associated with breast cancers in pre-menopausal women than in menopausal ones (5) , the former showing generally more aggressive tumors than the latter (10); (iii) there is an inverse relationship between the presence of estrogen receptors and the level of glutathione peroxidase expression in tumor cells (11) and between the number of estrogen receptors in the tumor cell cytosol and plasma vitamin E (12); (iv) tumor cells from poor prognosis breast cancers showed a lower level of polyunsaturated fatty acids than did better prognosis breast cancers (13) .
All these findings suggest that a change in oxidant-antioxidant status might accompany the proliferative capacities of tumor cells. The objective of this study was, therefore, to investigate whether the plasma concentrations of vitamin E and MDA in cancers other than breast cancers were associated with tumor aggressiveness. Biochemical measurements were performed before therapy in 129 patients affected by prostatic, ovarian, endometrial, lung and colorectal carcinomas. We showed that advanced stages of these cancers are associated with low MDA plasma levels, as in breast cancer. The relationship between tumor progression and vitamin E is affected by the very low plasma total cholesterol levels (pTC) found in most of the cancer sites considered here, whereas this is not the case with breast cancer (2, 14) . The connection between low levels of pTC and advanced stages of cancer was therefore also investigated.
Materials and methods

Patients and study design
This study was carried out at the Montpellier Cancer Center, France, from 1989 to 1992. It was cross-sectional in nature and comprised 129 subjects with cancers from several sites at various stages. All cases, from 26 to 87 years old, were recruited at the Cancer Center, except for most of the prostatic cases and a few ovarian and endometrial cancers, which were recruited from the general hospital. All tumors were histologically confirmed. Sixty six were colorectal cancers (33 colon, 16 male and 17 female; 33 rectum, 15 male and 18 female), 42 were hormone-related cancers (6 prostatic, 16 endometrial and 20 ovarian cancers) and 20 were lung cancers.
For each subject a questionnaire elicited information on socio-demographic data, familial and medical history, characteristics of smoking habits and food intake. The food frequency questionnaire previously used (2,3,5) was extended from 55 to 90 items to better cover fruit and vegetable intake and to provide information on cereals, which were not covered previously. The database of the program Fruit-d'Or (kindly given to us by Astra-Calve) for transforming foods to nutrients was UNIDAP, which largely used the values from McCance and Widdowson (15) . To adapt this database to French foods we modified it using the Regal database (16) and creating new codes for specific foods or regional recipes. The database is now made up of 900 items susceptible to transformation into 36 nutrients.
Assessment of tumor aggressiveness, tumor size (7") and invasion status (/) was based on clinical and paraclinical evaluation of the presence of nodes M.Saintot el al. and/or metastasis. Blood samples were drawn into sodium heparinate from each subject after overnight fasting before any kind of therapy. They were kept at 4°C in melting ice until laboratory treatment.
Laboratory methods
Plasma was separated by centrifugation and frozen at -78°C in several polypropylene freezer tubes within 3 h. Plasma was thawed only once and analyzed within 3 months of freezing. Vitamin E was determined by HPLC (17) with ultraviolet detection at 292 nm and automatic integration. Tocopherol acetate was used as the internal standard. Each run included a "spiked' standard and pooled plasma. Concentration of the standards was determined spectrophotometrically. The within-run and between-run coefficients of variation were 3 and 5% respectively and sensitivity was 10 nmol/1. The strong metabolic relationship between plasma vitamin E and the plasma lipid parameters (18) makes it necessary to express vitamin E levels as either vitamin E/total lipid or vitamin E/total cholesterol ratios (vitE/pTC) (19) . pTC was therefore assessed with a Coulter CPA apparatus using the Boehringer CHOD-PAP method. MDA was determined as its diethylthiobarbituric acid adduct by HPLC (20) with fluorescence detection (excitation, 515 nm; emission, 553 nm) and automatic integration. 1,1,3,3-Tetraethoxypropane (bismalondialdehyde) was used to generate MDA in situ under the acid conditions required to hydrolyze plasma lipoperoxides to MDA. Analytical recovery of the standard averaged 979K Each sample was analyzed in duplicate. A plasma pool sample was routinely assessed. The within-run and between- run coefficients of variation were 5 and 7% respectively and sensitivity was 2 nmol/1.
Statistical analysis
Statistical analysis was carried out with the SAS-PC statistical package (21). Analyses of variance and co-variance to test the null hypothesis concerning the difference between the mean values of blood analytes in the two relevant categories of cancer patients were carried out after logarithmic transformation of the data. This procedure was adopted because of the skewed distribution of values. Means and standard errors are presented in the original scale of measurement, however, for ease of interpretation. Allowance was made for age and sex when relevant. Two classes of T were considered (°£5 cm and >5 cm), because of the size range of the sample (only 12 tumors 2 cm). Two classes were likewise used for invasion status: the presence of nodes and/or metastasis (/+) and their absence (/-). Odds ratios (OR) were used as the measure of association between blood analytes (treated as categorical variables) and the characteristic of aggressiveness. These ratios, together with their 95% confidence intervals (CI), were calculated according to the Cornfield method (22) . The limits of the two classes of biological variables used for OR computation were based on tertiles for each T ^ 5 cm and /-sample, since they did not cover exactly the same subjects: the higher fertile was the reference category for cholesterol (3=5.12 and 2*5.29 mM respectively) and for MDA (3=0.30 and ==0.31 |iM respectively), the higher tertile was the reference category for vitamin E (3=21 (lM for both T =s 5 cm and /-) and vitE/total cholesterol (3=3.52, also for both samples).
Results
The patient sample is described in Table I . No significant differences in age, sex, smoking or relevant nutrient intake were found between patients in classes T =£ 5 cm and T >5 cm or /-and /+. Tumor size was >5 cm in 38% of patients and nodes and/or metastasis (/+) were found in 36%. Among the patients with large tumors, 30% were I-and among 1+ patients 24% had tumors of =s5 cm.
No correlation existed between pTC and the possibly relevant nutrients (saturated fat, polyunsaturated fat and linoleic acid). A correlation was established between plasma vitamin E, vitE/ pTC and vitamin E intake (r = 0.22, P = 0.02 and r = 0.26, P = 0.005 respectively). The usual correlation between plasma vitamin E and pTC was verified (r = 0.38, P = 0.0001) after adjusting for age and sex. Reciprocal adjustment was consequently computed for both variables. Table II shows that there was no difference between large tumors and small ones in the mean plasma concentrations of vitamin E, even after pTC adjustment or when the vitE/pTC ratio was used. Patients with large tumors had lower pTC and plasma MDA concentrations than those with small tumors and there was a significant difference in MDA. With regard to invasion status, there was a difference in vitamin E concentra- tions for /+ and /-which was marginally significant when adjusted for pTC and significant when considered as vitE/ pTC. The mean pTC and MDA concentrations were significantly lower in the presence of tumor invasion. There was a significant difference in cholesterol and MDA concentrations for both variables (size and invasion), but the difference was most significant for MDA levels and invasion. It is clear from Figure 1 that the cumulative percentage of /+ patients relative to MDA plasma concentration was very different from that of /-patients. The colorectal tumors showed a large enough range of tumor size and invasion stages to allow for the same comparison between mean plasma analyte concentrations and tumor progression (Table III) . Results follow the same trend (lower cholesterol, higher vitamin E and lower MDA for patients with signs of invasion), reaching significance for the difference between /-and /+ patients for vitamin E and MDA.
The association between blood analytes and the characteristic of aggressiveness was also measured by computing ORs (Tables IV and V) . The lower level of vitamin E and vitE/ pTC classes were associated with smaller tumors and less invasion, but in a non-significant fashion, as the confidence interval included 1. The lower level cholesterol and MDA classes were associated with larger tumors and greater invasion. Association with low pTC concentration was significant only for the /+ sample, whereas association with low MDA plasma concentration was significant for the T > 5 cm and /+ samples.
Discussion
The findings of this study strongly suggest that high plasma vitE/pTC ratios and low plasma concentrations of cholesterol and MDA are associated with large tumor size and significantly associated with tumor invasion. This appears to be a general effect, also specifically shown in breast cancer (10) and here in colorectal cancers.
Such a relationship cannot be said to be causal in nature, as the study is a cross-sectional one. It is possible, however, that high levels of vitamin E per mole cholesterol and low plasma cholesterol and plasma MDA concentrations are a consequence of tumor progression and a reflection of it.
One limitation of this study is the use made of clinical and paraclinical evaluation to assess invasion, which could result in the misclassification of patients considered as being free of nodes and/or metastasis. However, such non-differential misclassification is expected to bias the estimated association toward the null.
The significance of vitamin E plasma levels is another point to be discussed. Although vitamin E intake is not directly reflected in plasma levels, which depend on a transfer protein and on transport by low density lipoprotein particles, it may nevertheless interfere with plasma concentrations. We had nutritional data for only 105 patients. As there was no difference in daily consumption between patients with large and small tumors and between patients with nodes and/or metastasis, adjusting for vitamin E intake did not substantially change the strength of the association (results not shown). There was likewise no difference between the vitamin E intake of cases and the control in our previous breast cancer study (2, 3, 5) . There was no significant difference, either, among the other relevant nutrients in the present study (Table I) . As far as vitamin E is concerned, the cancer sites investigated have different characteristics from those of breast cancer. We (2, 3) and others (1,23) have reported higher vitamin E levels in breast cancer patients than in controls, these levels being significantly associated with breast cancer irrespective of cholesterol levels. Although cholesterol levels were also elevated in our study (2) , as reported by others (14), they were not significantly associated with breast cancer. This difference with regard to vitamin E and cholesterol observed between breast cancer and other forms of cancer might be explained by the early cancer stage in the breast cancer patients studied (all patients showed tumors <2 cm and were free of nodes and metastasis), whereas it has also been shown that cholesterol levels decrease as breast cancer progresses (24) . The low cholesterol levels of the far more advanced cancers considered here might thus impede high levels of plasma vitamin E, and only a slight increase in vitamin E per mole cholesterol may be found.
One question to be addressed is the significance of low pTC. It has been proposed that smoking may be a cause of both low serum total cholesterol and excess cancer mortality in general (25) . In our study smoking was found equally distributed in both classes, small and large tumors, /+ and Ipatients (Table I ), indicating that smoking habits were not confounding the association of low serum total cholesterol and tumor aggressiveness. It seems that only advanced cancers show low plasma cholesterol levels, as if tumor tissues contributed to their reduction. It may be that a high concentration of low density lipoprotein receptors on tumor cell membranes pumps in cholesterol (26) . There is another possible explanation, among others, related to an altered oxidant-antioxidant status in cancer cells. It has been shown (27) that cancer cells are resistant to doxorubicine or H 2 O2-induced oxidative stress when the p21 Ras protein is isoprenylated. Isoprenylation of the p21 Ras protein is mediated by mevalonate, an intermediary step in the cholesterol synthesis pathway. When mevalonate synthesis is inhibited by lovastatin, isoprenylation of the p21 Ras protein does not occur and the tumor cell is again sensitive to oxidative stress. As an alternative to the mechanistic hypothesis (26) , it can thus be said that a low pTC, possibly consequent on mevalonate being diverted from the cholesterol synthesis pathway towards isoprenylation of the p21 Ras protein, is concomitant with an oxidative stressresistant state of the tumor cell. In that case, alterations of pTC are coherent with low plasma levels of MDA, with high vitE/pTC and with the hypothesis proposed by Slater et al. (7) , after Szent-Gyogyi et al. (28) , which suggests that rapidly dividing cells tend to set an oxidant-antioxidant status favorable to their growth. This could be an adaptative response of cancer cells, as suggested by Cerutti (29) , e.g. a genetically induced resistance to oxidative stress with a high level of antioxidant and a low level of peroxidable substrates. Such a phenotype has been shown in animal tumor cells in vivo and in vitro (30) (31) (32) (33) and in human cells in vitro (8) .
These findings might appear contradictory to the association of antioxidants with reduced cancer risk, which has been established by experimental and epidemiological research. It must be underlined that the hypothesis proposed by Slater et al. (7) and Szent-Gyogyi et al. (28) deals with cancer progression. However, the initiation and induction stages reactive oxygen species are mutagenic and play a role in signal transmission for growth factor synthesis, hence, antioxidants may well decrease cancer risk in these early stages. There are now several lines of evidence showing that oxidants and antioxidants act differently in different stages of carcinogenesis, possibly with various mechanisms (34, 35) .
